Genomics,Multiomics

Dataset Information

3

Imiquimod treated Basal Cell Carcinoma


ABSTRACT: Imiquimod is a Toll-like receptor (TLR)-7 agonist capable of inducing complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We hypothesized that the characterization of the early transcriptional events induced by imiquimod may provide insights about immunological events preceding acute tissue and/or tumor rejection. We report a paired analysis of adjacent punch biopsies obtained pre- and post-treatment from 36 patients with BCC subjected to local application of imiquimod (N = 22) or vehicle cream (N=14) in a blinded, randomized protocol. Four treatments were assessed (q12 applications for 2 or 4 days, or q24 hrs for 4 or 8 days). RNA was amplified and hybridized to 17.5K cDNA arrays. All treatment schedules similarly affected the transcriptional profile of BCC; however, the q12 X 4days regimen, associated with highest effectiveness, induced the most changes with 637 genes unequivocally stimulated by imiquimod. A minority of transcripts (98 genes) confirmed previous reports of interferon-  involvement. The remaining 539 genes portrayed additional immunological functions predominantly involving the activation of cellular innate and adaptive immune-effector mechanisms. Importantly, these effector signatures recapitulate previous observations of tissue rejection in the context of cancer immunotherapy, acute allograft rejection and autoimmunity. This study based on a powerful and reproducible model of cancer eradication by innate immune mechanisms provides the first insight in humans of the early transcriptional events associated with immune rejection. This model is likely representative of constant immunological pathways through which innate and adaptive immune responses combine to induce tissue destruction. Keywords: compound treatment design We report a paired analysis of adjacent punch biopsies obtained pre- and post-treatment from 36 patients with BCC subjected to local application of imiquimod (N = 22) or vehicle cream (N=14) in a blinded, randomized protocol. Four treatments were assessed (q12 applications for 2 or 4 days, or q24 hrs for 4 or 8 days). RNA was amplified and hybridized to 17.5K cDNA arrays.

OTHER RELATED OMICS DATASETS IN: PRJNA96617

ORGANISM(S): Homo sapiens  

SUBMITTER: Francesco Maria Marincola  

PROVIDER: E-GEOD-5121 | ArrayExpress | 2006-10-04

SECONDARY ACCESSION(S): GSE5121PRJNA96617

REPOSITORIES: GEO, ArrayExpress

Dataset's files

Source:
Action DRS
E-GEOD-5121.README.txt Txt
E-GEOD-5121.idf.txt Idf
E-GEOD-5121.processed.1.zip Processed
E-GEOD-5121.sdrf.txt Txt
Items per page:
1 - 4 of 4
altmetric image

Publications

Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.

Panelli Monica C MC   Stashower Mitchell E ME   Slade Herbert B HB   Smith Kina K   Norwood Christopher C   Abati Andrea A   Fetsch Patricia P   Filie Armando A   Walters Shelley-Ann SA   Astry Calvin C   Aricó Eleonora E   Zhao Yingdong Y   Selleri Silvia S   Wang Ena E   Marincola Francesco M FM  

Genome biology 20070101 1


<h4>Background</h4>Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We hypothesized that the characterization of the early transcriptional events induced by imiquimod may provide insights about immunological events preceding acute tissue and/or tumor rejection.<h4>Results</h4>We report a paired analysis of adjacent punch biopsies obtained pre- and post-treatment from 36 patients with BCC subjected t  ...[more]

Similar Datasets

2007-01-01 | S-EPMC1839129 | BioStudies
2012-01-01 | S-EPMC3532314 | BioStudies
2010-05-25 | E-GEOD-8778 | ArrayExpress
2016-01-01 | S-EPMC4812152 | BioStudies
2012-06-24 | E-GEOD-27126 | ArrayExpress
2012-10-01 | E-GEOD-32611 | ArrayExpress
2012-01-01 | S-EPMC3580198 | BioStudies
1000-01-01 | S-EPMC3898320 | BioStudies
2010-06-24 | E-GEOD-20032 | ArrayExpress
2017-01-01 | S-EPMC5567915 | BioStudies